BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sagnelli C, Macera M, Pisaturo M, Zampino R, Coppola M, Sagnelli E. Occult HBV infection in the oncohematological setting. Infection. 2016;44:575-582. [PMID: 27076347 DOI: 10.1007/s15010-016-0891-1] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
Number Citing Articles
1 Fabbri G, Mastrorosa I, Vergori A, Mazzotta V, Pinnetti C, Grisetti S, Zaccarelli M, Ammassari A, Antinori A. Reactivation of occult HBV infection in an HIV/HCV Co-infected patient successfully treated with sofosbuvir/ledipasvir: a case report and review of the literature. BMC Infect Dis 2017;17:182. [PMID: 28249574 DOI: 10.1186/s12879-017-2287-y] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 3.2] [Reference Citation Analysis]
2 Ma K, Shokoohi S, Reau N. Reactivation of Occult HBV Infection in Patients Cured of HCV With Direct-Acting Antivirals. Curr Treat Options Infect Dis 2017;9:380-8. [DOI: 10.1007/s40506-017-0134-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
3 Castelli R, Ferraris L, Pantaleo G, Lambertenghi Deliliers G, Cicardi M. High rate of hepatitis B viral breakthrough in elderly non-Hodgkin lymphomas patients treated with Rituximab based chemotherapy. Digestive and Liver Disease 2016;48:1394-7. [DOI: 10.1016/j.dld.2016.08.113] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 2.5] [Reference Citation Analysis]
4 Matsuda H, Hiramatsu K, Akazawa Y, Nosaka T, Saito Y, Ozaki Y, Hayama R, Takahashi K, Naito T, Ofuji K, Ohtani M, Nemoto T, Hida Y, Kimura H, Soya Y, Nakamoto Y. Genetic polymorphism and decreased expression of HLA class II DP genes are associated with HBV reactivation in patients treated with immunomodulatory agents. J Med Virol 2018;90:712-20. [PMID: 29283185 DOI: 10.1002/jmv.25011] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
5 He Q, Song X, Huang Y, Huang W, Ye B, Luo H, Luo H, Wu L, Wang Z, Chen W, Zhang L. Dexamethasone Stimulates Hepatitis B Virus (HBV) Replication Through Autophagy. Med Sci Monit 2018;24:4617-24. [PMID: 29972684 DOI: 10.12659/MSM.906250] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
6 Sagnelli C, Pisaturo M, Calò F, Martini S, Sagnelli E, Coppola N. Reactivation of hepatitis B virus infection in patients with hemo-lymphoproliferative diseases, and its prevention. World J Gastroenterol 2019; 25(26): 3299-3312 [PMID: 31341357 DOI: 10.3748/wjg.v25.i26.3299] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 13] [Article Influence: 5.3] [Reference Citation Analysis]
7 Sagnelli E, Macera M, Russo A, Coppola N, Sagnelli C. Epidemiological and etiological variations in hepatocellular carcinoma. Infection. 2020;48:7-17. [PMID: 31347138 DOI: 10.1007/s15010-019-01345-y] [Cited by in Crossref: 35] [Cited by in F6Publishing: 41] [Article Influence: 11.7] [Reference Citation Analysis]
8 Sagnelli C, Sagnelli E. Towards the worldwide eradication of hepatitis B virus infection: A combination of prophylactic and therapeutic factors. World J Clin Infect Dis 2019; 9(2): 11-22 [DOI: 10.5495/wjcid.v9.i2.11] [Cited by in CrossRef: 1] [Article Influence: 0.3] [Reference Citation Analysis]
9 Wang H, Xiang Y, Li X, Liu S, Liu L. High lymphocyte‑to‑monocyte ratio is associated with low α‑fetoprotein expression in patients with hepatitis B virus‑associated hepatocellular carcinoma. Mol Med Rep 2020;22:2673-84. [PMID: 32945410 DOI: 10.3892/mmr.2020.11387] [Reference Citation Analysis]
10 Marrone A, Capoluongo N, D'Amore C, Pisaturo M, Esposito M, Guastafierro S, Siniscalchi I, Macera M, Boemio A, Onorato L, Rinaldi L, Minichini C, Adinolfi LE, Sagnelli E, Mastrullo L, Coppola N. Eighteen-month lamivudine prophylaxis on preventing occult hepatitis B virus infection reactivation in patients with haematological malignancies receiving immunosuppression therapy. J Viral Hepat. 2018;25:198-204. [PMID: 29029365 DOI: 10.1111/jvh.12802] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.2] [Reference Citation Analysis]
11 Gachara G, Magoro T, Mavhandu L, Lum E, Kimbi HK, Ndip RN, Bessong PO. Characterization of occult hepatitis B virus infection among HIV positive patients in Cameroon. AIDS Res Ther 2017;14:11. [PMID: 28270215 DOI: 10.1186/s12981-017-0136-0] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 2.6] [Reference Citation Analysis]